Merck’s PD-1 Inhibitor Pembrolizumab Subcutaneous Injection Approved in China
September 30, 2026 — 03:31 CST
This Data Is Locked!
This area is available only to Subscribers.
Merck, a pharmaceutical company based in Kenilworth, New Jersey, announced that its PD-1 inhibitor pembrolizumab subcutaneous injection has been approved by the National Medical Products... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
